MacroGenics, Inc. (MGNX)

Market Cap	205.86M
Revenue (ttm)	141.33M
Net Income (ttm)	-97.62M
Shares Out	62.76M
EPS (ttm)	-1.56
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	644,270
Open	3.460
Previous Close	3.480
Day's Range	3.220 - 3.460
52-Week Range	2.951 - 21.880
Beta	2.08
Analysts	Buy
Price Target	8.57 (+161.28%)
Earnings Date	Nov 5, 2024

About MGNX

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company’s pipeline of immuno-oncology product candidates includes MGC018, an antibod...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 10, 2013
• Employees: 339
• Stock Exchange: NASDAQ
• Ticker Symbol: MGNX
• Website: https://www.macrogenics.com

Financial Performance

In 2023, MacroGenics's revenue was $58.75 million, a decrease of -61.33% compared to the previous year's $151.94 million. Losses were -$9.06 million, -92.44% less than in 2022.

Analyst Forecast

According to 11 analysts, the average rating for MGNX stock is "Buy." The 12-month stock price forecast is $8.57, which is an increase of 161.28% from the latest price.

Price Target

$8.57

(161.28% upside)

Analyst Consensus: Buy